Trial · NCT03809429
Results by group126
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 126
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Oocytes Retrieved | FE 999049 + GnRH Agonist (GONAPEPTYL) | 11.1 | Standard Deviation 5.9 | Oocytes | |
| Number of Oocytes Retrieved | FE 999049 + GnRH Antagonist (CETROTIDE) | 9.6 | Standard Deviation 5.5 | Oocytes | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Agonist (GONAPEPTYL) | Excessive response | 2 | participants | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Antagonist (CETROTIDE) | Excessive response | 3 | participants | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Agonist (GONAPEPTYL) | Poor response | 1 | participants | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Antagonist (CETROTIDE) | Poor response | 3 | participants | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Agonist (GONAPEPTYL) | Other reason | 1 | participants | |
| Proportion of Subjects With Cycle Cancellation Due to Poor Ovarian Response or Excessive Ovarian Response | FE 999049 + GnRH Antagonist (CETROTIDE) | Other reason | 1 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Transfer cancellation | 27 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Transfer cancellation | 30 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Reason for transfer cancellation: Adverse Event | 5 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Reason for transfer cancellation: Adverse Event | 8 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Reason for transfer cancellation: Risk of OHSS | 1 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Reason for transfer cancellation: Risk of OHSS | 1 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Reason for transfer cancellation: No blastocyst | 13 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Reason for transfer cancellation: No blastocyst | 18 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Reason for transfer cancellation: COVID-19 | 3 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Reason for transfer cancellation: COVID-19 | 1 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Agonist (GONAPEPTYL) | Reason for transfer cancellation: Other reason | 5 | participants | |
| Proportion of Subjects With Blastocyst Transfer Cancellation After Oocyte Retrieval Due to (Risk of) Ovarian Hyperstimulation Syndrome (OHSS) | FE 999049 + GnRH Antagonist (CETROTIDE) | Reason for transfer cancellation: Other reason | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03809429/results